According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Three gurus are invested in Akebia Therapeutics Inc. (AKBA).
The company designs, manufactures and commercialize novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. It has a market cap of $589.31 million.
The stock is trading with a price-book (P/B) ratio of 2.55. The current price of $10.36 is 48.84% below its 52-week high and 16.01% above its 52-week low. Over the past 10 years, it has returned a loss of 61%.
The company’s largest shareholder among the gurus is Jim Simons (Trades, Portfolio) with 4.43% of outstanding shares followed by Steven Cohen (Trades, Portfolio) with 0.34% and Paul Tudor Jones (Trades, Portfolio) with 0.04%.
Four gurus have positions in Ligand Pharmaceuticals Inc. (LGND).
The company develops and acquires technologies that aid in creating medicine. It has a market cap of $4.03 billion. Its revenue has grown 18.20% annually over the past 10 years.
The stock is trading with a P/B ratio of 8.40. The current price of $189.42 is 3.63% below its 52-week high and 75.98% above its 52-week low. Over the past 10 years, it has returned a gain of 818%.
Simons is the largest shareholder of the company among the gurus with 1.71% of outstanding shares followed by Columbia Wanger (Trades, Portfolio) with 1.45%, Ken Fisher (Trades, Portfolio) with 0.22% and Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) with 0.16%.
Three gurus are invested in Neurocrine Biosciences Inc. (NBIX).
The company develops drugs for the treatment of neurological and endocrine-related diseases. has a market cap of $8.51 billion.
The stock is trading with a P/B ratio of 23.30. The current price of $94.64 is 0.88% below its 52-week high and 126.63% above its 52-week low. Over the past decade, the stock has bounced 1,922%.
The company’s largest shareholder among the gurus is Simons with 0.18% of outstanding shares followed by Cohen with 0.08% and Pioneer Investments (Trades, Portfolio) with 0.07%.
Five gurus have positions in Vertex Pharmaceuticals Inc. (VRTX).
The company designs, manufactures and commercialize small molecule drugs for patients with serious diseases in specialty markets. It has a market cap of $40 million and its revenue has grown 8.80% over the past 10 years.
The stock is trading with a P/B ratio of 16.66. The current price of $156.97 is 11.94% below its 52-week high and 33.73% above its 52-week low. Over the past 10 years, it has returned a gain of 495%.
Vanguard Health Care Fund (Trades, Portfolio) is the largest shareholder of the company among the gurus with 3.12% of outstanding shares followed by Simons with 1.12%, Spiros Segalas (Trades, Portfolio) with 0.74% and Pioneer Investments (Trades, Portfolio) with 0.5%.
Four gurus are invested in Macrogenics Inc. (MGNX).
The company discovers and develops monoclonal antibody-based therapeutics for the treatment of cancer. It has a market cap of $920.43 million.
The stock is trading with a P/B ratio of 3.27. The current price of $21.81 is 33.38% below its 52-week high and 51.88% above its 52-week low. Over the past 10 years, it has returned a loss of 13%.
The company’s largest shareholder among the gurus is Cohen with 2.57% of outstanding shares followed by Columbia Wanger (Trades, Portfolio) with 0.97%, Simons with 0.95%, Jones with 0.09% and Joel Greenblatt (Trades, Portfolio) with 0.02%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
